GlobalData has forecast the uveitis market across the UK, US, France, Germany, Italy, Spain and Japan to grow from $522.5bn in 2023 to $1.5bn in 2033.
The company’s latest report, ‘Uveitis: Opportunity Assessment and Forecast’, revealed that the projected growth is supported by the anticipated launch of six novel pipeline agents, coupled with the growing uveitis population.
Sara Reci, managing pharma analyst at GlobalData, said that, while corticosteroids were well-established in the uveitis space, key opinion leaders had emphasised that the most pressing unmet needs in the management of uveitis included ‘improving the safety and side-effect profile, longer acting therapies, drugs with other mechanisms of action, and greater awareness and education of physicians’.
